Needham & Company raised its price target on CONMED (NASDAQ: CNMD) to $73.00 (from $71.00) while maintaining a Buy rating.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

CONMED (CNMD) PT Raised to $61 at Piper JaffrayApril 26, 2018 6:40 AM Conmed (CNMD) Tops Q1 EPS by 9c; Raises OutlookApril 25, 2018 4:15 PM CONMED Corporation Announces First Quarter 2018 Financial ResultsApril 25, 2018 4:01 PM